These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24283946)

  • 1. Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
    He M; Fan W; Zhang X
    J Hematol Oncol; 2013 Oct; 6(1):80. PubMed ID: 24283946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
    Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
    Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.
    Huang WW; Huang C; Liu J; Zheng HY; Lin L
    PLoS One; 2012; 7(7):e40783. PubMed ID: 22844410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
    Leal T; Tevaarwerk A; Love R; Stewart J; Binkley N; Eickhoff J; Parrot B; Mulkerin D
    Clin Breast Cancer; 2010 Dec; 10(6):471-6. PubMed ID: 21147691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
    Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
    Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH
    J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
    de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
    Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
    Yang L; Du S
    Medicine (Baltimore); 2015 Oct; 94(42):e1822. PubMed ID: 26496320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
    Valachis A; Polyzos NP; Coleman RE; Gnant M; Eidtmann H; Brufsky AM; Aft R; Tevaarwerk AJ; Swenson K; Lind P; Mauri D
    Oncologist; 2013; 18(4):353-61. PubMed ID: 23404816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast-cancer adjuvant therapy with zoledronic acid.
    Coleman RE; Marshall H; Cameron D; Dodwell D; Burkinshaw R; Keane M; Gil M; Houston SJ; Grieve RJ; Barrett-Lee PJ; Ritchie D; Pugh J; Gaunt C; Rea U; Peterson J; Davies C; Hiley V; Gregory W; Bell R;
    N Engl J Med; 2011 Oct; 365(15):1396-405. PubMed ID: 21995387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.